Cargando…
The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial
BACKGROUND: Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural effusion. Breathlessness, dyspnea and other symptoms often seriously distress and affect the quality of life. The external application of mirabilite and rhubarb (EAMR) combined with intrathoracic infu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899874/ https://www.ncbi.nlm.nih.gov/pubmed/33607823 http://dx.doi.org/10.1097/MD.0000000000024758 |
_version_ | 1783654100427079680 |
---|---|
author | Zhang, Huachun Jiang, Mengyuan Gao, Lirong Lin, Zhen |
author_facet | Zhang, Huachun Jiang, Mengyuan Gao, Lirong Lin, Zhen |
author_sort | Zhang, Huachun |
collection | PubMed |
description | BACKGROUND: Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural effusion. Breathlessness, dyspnea and other symptoms often seriously distress and affect the quality of life. The external application of mirabilite and rhubarb (EAMR) combined with intrathoracic infusion of cisplatin, as an alternative treatment for MPE, is popular in China. The study aims to assess its effectiveness and safety combined with intrathoracic chemotherapy. METHODS: This study is a prospective, randomized controlled clinical trial. Patient visits were performed at baseline and days 14 and 28 after treatment. Clinical outcomes were measured after chest drain placement using the criterion of efficacy refer to WHO standard, and QLQ-C30 questionnaire. RESULTS: Database records of patients treated in our institution for MPE between October, 2016 and March, 2019. The study included 84 eligible patients. They were categorized with a randomization schedule into treatment group (N = 42) and control group (N = 42). There is statistical significance in the comparison of the total effective rate between these 2 groups (66.67% vs 54.76%, P < .05). Furthermore, there is statistical significance in the comparison of items of Physical (1.95 ± 0.50 vs 2.19 ± 0.58%, P < .05), Pain (1.98 ± 0.42 vs 2.07 ± 0.32, P < .05), and Global Health (1.23 ± 0.64 vs 1.13 ± 0.23%, P < .05) between these 2 groups. None of the patients had adverse reactions such as skin allergy and chest tightness. CONCLUSIONS: The total effective rate of treatment group using extra external application of mirabilite rhubarb powder is significantly higher than that of control group. The improvement of patients’ clinical symptoms is greater in treatment group and no adverse reactions is found. Therefore, external application of mirabilite and rhubarb combined with intrathoracic infusion of cisplatin is an effective method for the treatment of MPE, which is worth popularizing. |
format | Online Article Text |
id | pubmed-7899874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-78998742021-02-24 The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial Zhang, Huachun Jiang, Mengyuan Gao, Lirong Lin, Zhen Medicine (Baltimore) 3800 BACKGROUND: Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural effusion. Breathlessness, dyspnea and other symptoms often seriously distress and affect the quality of life. The external application of mirabilite and rhubarb (EAMR) combined with intrathoracic infusion of cisplatin, as an alternative treatment for MPE, is popular in China. The study aims to assess its effectiveness and safety combined with intrathoracic chemotherapy. METHODS: This study is a prospective, randomized controlled clinical trial. Patient visits were performed at baseline and days 14 and 28 after treatment. Clinical outcomes were measured after chest drain placement using the criterion of efficacy refer to WHO standard, and QLQ-C30 questionnaire. RESULTS: Database records of patients treated in our institution for MPE between October, 2016 and March, 2019. The study included 84 eligible patients. They were categorized with a randomization schedule into treatment group (N = 42) and control group (N = 42). There is statistical significance in the comparison of the total effective rate between these 2 groups (66.67% vs 54.76%, P < .05). Furthermore, there is statistical significance in the comparison of items of Physical (1.95 ± 0.50 vs 2.19 ± 0.58%, P < .05), Pain (1.98 ± 0.42 vs 2.07 ± 0.32, P < .05), and Global Health (1.23 ± 0.64 vs 1.13 ± 0.23%, P < .05) between these 2 groups. None of the patients had adverse reactions such as skin allergy and chest tightness. CONCLUSIONS: The total effective rate of treatment group using extra external application of mirabilite rhubarb powder is significantly higher than that of control group. The improvement of patients’ clinical symptoms is greater in treatment group and no adverse reactions is found. Therefore, external application of mirabilite and rhubarb combined with intrathoracic infusion of cisplatin is an effective method for the treatment of MPE, which is worth popularizing. Lippincott Williams & Wilkins 2021-02-19 /pmc/articles/PMC7899874/ /pubmed/33607823 http://dx.doi.org/10.1097/MD.0000000000024758 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 3800 Zhang, Huachun Jiang, Mengyuan Gao, Lirong Lin, Zhen The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial |
title | The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial |
title_full | The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial |
title_fullStr | The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial |
title_full_unstemmed | The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial |
title_short | The clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: A prospective, randomized, controlled clinical trial |
title_sort | clinical efficacy of external application of mirabilite and rhubarb combined with intrathoracic chemotherapy in treating malignant pleural effusion: a prospective, randomized, controlled clinical trial |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899874/ https://www.ncbi.nlm.nih.gov/pubmed/33607823 http://dx.doi.org/10.1097/MD.0000000000024758 |
work_keys_str_mv | AT zhanghuachun theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT jiangmengyuan theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT gaolirong theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT linzhen theclinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT zhanghuachun clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT jiangmengyuan clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT gaolirong clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial AT linzhen clinicalefficacyofexternalapplicationofmirabiliteandrhubarbcombinedwithintrathoracicchemotherapyintreatingmalignantpleuraleffusionaprospectiverandomizedcontrolledclinicaltrial |